Basic immunology of antibody targeted radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages S8-

  Wong, Jeffrey Y C ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antibodies; Radioimmunotherapy; Radionuclide; STaRT

Indexed keywords

ANTIBODIES; ANTIGENS; IMMUNOLOGY; ONCOLOGY; RADIOISOTOPES; TUMORS;

RADIOIMMUNOTHERAPY;

RADIOTHERAPY;

ASTATINE 211; BISMUTH 212; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; COPPER 67; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM 186; TUMOR ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG TARGETING; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

EID: 33748443549     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.05.056     Document Type: Article

References (43)

1. Beierwaltes W.H. Radioiodine-labelled compounds previously or currently used for tumour localization (1974), International Atomic Energy Agency, Vienna, Austria 47 In Proceedings of an Advisory Group Meeting on Tumour Localization with Radioactive Agents. Panel Proceedings Series.
2. Order S.E., Stillwagon G.B., Klein J.L., et al. Iodine 131 anti-ferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3 (1985) 1573-1582
3. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
4. Khazaeli M.B., Conry R.M., and LoBuglio A.F. Human immune response to monoclonal antibodies. J Immunother 15 (1994) 42-52
5. Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56 (1996) 2123-2129
6. Esteban J.M., Wong J.Y.C., Wanek P., Beatty B.G., and Beatty J.D. CEA expression of resurgent human colon carcinoma after treatment with therapeutic doses of Y-90-anti-CEA monoclonal antibody. Antibody, Immunoconjugates, and Radiopharmaceuticals 1 (1990) 50
7. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (Suppl) 50 (1990) 814s-819s
8. Colcher D., Bird R., Roselli M., et al. In vivo tumor targeting of a recombinant single-chain antigen binding protein. JNCI 82 (1990) 1191-1197
9. Wu A.M., Chen W., Raubitschek A.A., et al. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 2 (1996) 21-36
10. Adams G.P., Schier R., McCall A.M., et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77 (1998) 1405-1412
11. Rossi E.A., Chang C.H., McBride W., et al. Development of bispecific diabodies for tumor therapy by pretargeting methodology. Proc Am Assoc Cancer Res 43 (2002) 1015
12. Wu A.M., Williams L.E., Zieran L., et al. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 4 (1999) 47-58
13. Goel A., Augustine S., Baranowska-Kortylewicz J., et al. Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using I131-labeled multivalent CC49 single-chain FVs. Clin Cancer Res 7 (2001) 175-184
14. Pavlinkova G., Booth B.J., Batra S.K., and Colcher D. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res 5 (1999) 2613-2619
15. Rossi E.A., Chang C.H., Karacay H., Zeng L., Sharkey R., and Goldenberg D.M. Tumor targeting with humanized anti-CEA diabodies, triabodies, and tetrabodies. Proc Am Assoc Cancer Res 43 (2002) 1015
16. Yazaki P.J., Wu A.M., Tsai S.W., et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments. Bioconjugate Chem 12 (2001) 220-228
17. Iliades P., Kortt A.A., and Hudson P.J. Triabodies: Single chain Fv fragments without a linker form trivalent trimers. Fed Europ Biochem Soc Lett 409 (1997) 437-441
18. King D.J., Turner A., Farnsworth A.P., et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54 (1994) 6176-6185
19. Shu L., Qi C.F., Schlom J., and Kashmiri S.V. Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci U S A 90 (1993) 7995-7999
20. Slavin-Chiorini D.C., Horan Hand P.H., Kashmiri S.V., Calvo B., Zaremba S., and Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 53 (1993) 97-103
21. Slavin-Chiorini D.C., Kashmiri S.V.S., Lee H.-S., et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 12 (1997) 305-316
22. Santos A.D., Kashmiri S.V., Hand P.H., Schlom J., and Padlan E.A. Generation and characterization of a single gene-encoded single-chain tetravalent antitumor antibody. Clin Cancer Res 5 10 Suppl (1999) 3118s-3123s
23. Breitz H.B., Weiden P.L., Vanderheyden J.-L., et al. Clinical experience with Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 33 (1992) 1099-1112
24. Meredith R.F., Bueschen A.J., Khazaeli M.B., et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 35 (1994) 1017-1022
25. 131I-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12 (1994) 1561-1571
26. Mulligan T., Carrasquillo J.A., Chung Y., et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1 (1995) 1447-1454
27. 131I-labeled COL-1 in patients with gastroinestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 6 (1996) 1798-1809
28. DeNardo S.J., Kramer E.L., O'Donnell R.T., et al. Radioimmunotherapy for breast cancer using Indium-111/Yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 38 (1997) 1180-1185
29. Behr T.M., Sharkey R.M., Juweid M.E., et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38 (1997) 858-870
30. Juweid M., Swayne L.C., Sharkey R.M., et al. Prospects of radioimmunotherapy in epithelial ovarian cancer: Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Gynecol Oncol 67 (1997) 259-271
31. Divgi C.R., Bander N.H., Scott A.M., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4 (1998) 2729-2739
32. Meredith R.F., Khazaeli M.B., Liu T., et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33 (1992) 1648-1653
33. Weiden P.L., Breitz H.B., Seiler C.A., et al. Rhenium-186-labeled chimeric antibody NR-LU-13: Pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med 34 (1993) 2111-2119
34. Meredith R.F., Khazaeli M.B., Plott W.E., et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 36 (1995) 2229-2233
35. DeNardo S.J., O'Grady L.F., Richman C.M., et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 17 3B (1997) 1745-1751
36. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5 10 Suppl. (1999) 3268s-3274s
37. 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 41 (2000) 1168-1176
38. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41 (2000) 1999-2010
39. Wong J.Y.C., Chu D.Z., Yamauchi D.M., et al. Phase I radioimmunotherapy trials evaluating Y-90 labeled anti-CEA chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 6 (2000) 3855-3863
40. Kramer E.L., Liebes L., Wasserheit C., et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 4 (1998) 1679-1688
41. Hajjar G., Sharkey R.M., Burton J., et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorect Cancer 2 (2002) 31-42
42. 90Y-DOTA-huJ591: Radiolabeled anti-PSMA humanized monoclonal antibody for the treatment of prostate cancer: Phase I dose escalation studies. J Nucl Med 43 (2002) 158P
43. 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9 Suppl (2003) 3961s-3972s